Free Newsletter
FDA mulls behind-the-counter drug sales
Once, the gap between prescription drugs and over-the-counter sales was a wide No Man's Land where few products roamed. Now, the FDA may settle more medications in this country, known as behind-the-counter (BTC) sales, in part to improve access for the uninsured.
The agency is seeking public comment on the potential move, which would allow patients to buy certain remedies after consultation with a pharmacist. Though the FDA won't cite specific meds that might be included, experts cite birth control pills and cholesterol-lowering remedies as possibilities.
- see the AP article
Related Articles:
House overhauls, passes PDUFA. Report
FDA clears Plan B, ending FDA confirmation fight. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: